Galaxy Capital Trading’s Biogen BIIB Stock Holding History

Galaxy Capital Trading’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-2,600	Closed	-$626K	–	164
2013 Q3	$626K	Buy	+2,600	New	+$582K	0.48%	72

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Galaxy Capital Trading's BIIB Position: Q4 2013 in Review

Galaxy Capital Trading sold out of Biogen (BIIB) in Q4 2013, closing a stake of 2,600 shares — an estimated $626K sold.

Galaxy Capital Trading first reported a position in BIIB in Q3 2013 and held it in 1 quarter. The position peaked at $626K in Q3 2013. 738 funds tracked by Wall St. Rank hold BIIB as of Q4 2013.

Galaxy Capital Trading reported no remaining Biogen position as of Q4 2013 after selling out during the quarter.
Galaxy Capital Trading sold 2,600 Biogen shares in Q4 2013, an estimated $626K.
Galaxy Capital Trading first reported a position in Biogen in Q3 2013 and held it in 1 quarter.
Galaxy Capital Trading's Biogen position peaked at $626K in Q3 2013.
738 funds tracked by Wall St. Rank held Biogen as of Q4 2013.

Based on Galaxy Capital Trading's 13F filing for Q4 2013, filed 26 Feb 2014.